Zymeworks Inc.

Zymeworks Bc Inc.

Kevin Hamblett

James R Rich

Stuart Daniel Barnscher

Gerald J Rowse

Rupert H Davies

Vincent K C Fung

Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR ≥3.9 when administered at the same toxin dose.

Anti-HER2 biparatopic antibody-drug conjugates and methods of use

Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (&#x3c;3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR&#x2265;3.9 when administered at the same toxin dose.

Growing community of inventors

Seattle, WA, United States of America

Kevin Hamblett